Literature DB >> 16773562

Distinct expression profiles for PTEN transcript and its splice variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome.

Marta S Sarquis1, Shipra Agrawal, Lei Shen, Robert Pilarski, Xiao-Ping Zhou, Charis Eng.   

Abstract

Cowden syndrome (CS) and Bannayan-Riley-Ruvalcaba syndrome (BRRS) are autosomal dominant hamartoma syndromes. Germline PTEN mutations have been associated with 85% of CS cases and 65% of BRRS cases and also with other disorders, which are collectively referred to as the "PTEN hamartoma tumor syndrome." The human PTEN gene has been previously found to express two naturally occurring splice variants (SVs). Recently, we identified eight novel naturally occurring PTEN SVs that result in different downstream signaling effects: SV3a, SV3b, SV3c (inclusion of various lengths of intron 3 3' of exon 3), SV5a, SV5b, SV5c, SV5d (inclusion of various lengths of intron 5 3' of exon 5), and SV Delta Ex6 (deletion of exon 6). We therefore sought to characterize the relative expression of 5', middle, and 3' full-length PTEN mRNA (FL-PTEN) and also of these eight PTEN SVs in 85 (65 female and 20 male) patients with CS/BRRS (with or without PTEN mutations) compared with 27 controls, using a SYBR green quantitative polymerase chain reaction method. Significantly reduced FL-PTEN levels were found in the probands, compared with those of controls (P < .01). Apart from FL-PTEN, SV3a is the most consistently relatively underexpressed in patients compared with controls. The patients showed relative underexpression of SV3a and SV3b and overexpression of SV5b (P = .005, P = .02, and P = .04, respectively). Indeed, there appears to be an SV expressional genotype-phenotype correlation in which the SV expressional profiles are distinct among CS, CS-like, and BRRS. The reduced FL-PTEN transcript expression, associated with differential expression of PTEN SVs, regardless of PTEN mutation status, supports the concept that modulation of PTEN inactivation may also occur at the transcription level influencing the specific phenotypes seen in these syndromes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16773562      PMCID: PMC1474112          DOI: 10.1086/504392

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  24 in total

Review 1.  RNA processing and human disease.

Authors:  A V Philips; T A Cooper
Journal:  Cell Mol Life Sci       Date:  2000-02       Impact factor: 9.261

2.  Will the real Cowden syndrome please stand up: revised diagnostic criteria.

Authors:  C Eng
Journal:  J Med Genet       Date:  2000-11       Impact factor: 6.318

3.  P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase.

Authors:  M P Myers; J P Stolarov; C Eng; J Li; S I Wang; M H Wigler; R Parsons; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

4.  Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer.

Authors:  Shipra Agrawal; Charis Eng
Journal:  Hum Mol Genet       Date:  2006-01-25       Impact factor: 6.150

5.  Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.

Authors:  D J Marsh; V Coulon; K L Lunetta; P Rocca-Serra; P L Dahia; Z Zheng; D Liaw; S Caron; B Duboué; A Y Lin; A L Richardson; J M Bonnetblanc; J M Bressieux; A Cabarrot-Moreau; A Chompret; L Demange; R A Eeles; A M Yahanda; E R Fearon; J P Fricker; R J Gorlin; S V Hodgson; S Huson; D Lacombe; C Eng
Journal:  Hum Mol Genet       Date:  1998-03       Impact factor: 6.150

6.  Different splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of PTEN.

Authors:  Shipra Agrawal; Robert Pilarski; Charis Eng
Journal:  Hum Mol Genet       Date:  2005-07-13       Impact factor: 6.150

7.  PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.

Authors:  D J Marsh; J B Kum; K L Lunetta; M J Bennett; R J Gorlin; S F Ahmed; J Bodurtha; C Crowe; M A Curtis; M Dasouki; T Dunn; H Feit; M T Geraghty; J M Graham; S V Hodgson; A Hunter; B R Korf; D Manchester; S Miesfeldt; V A Murday; K L Nathanson; M Parisi; B Pober; C Romano; C Eng
Journal:  Hum Mol Genet       Date:  1999-08       Impact factor: 6.150

8.  Study of the PTEN gene expression and FAK phosphorylation in human hepatocarcinoma tissues and cell lines.

Authors:  Lineng Zhang; Qiang Yu; Jianyu He; Xiliang Zha
Journal:  Mol Cell Biochem       Date:  2004-07       Impact factor: 3.396

Review 9.  Are aberrant transcripts of FHIT, TSG101, and PTEN/MMAC1 oncogenesis related?

Authors:  N M Wang; J G Chang
Journal:  Int J Mol Med       Date:  1999-05       Impact factor: 4.101

Review 10.  Splice variants as cancer biomarkers.

Authors:  Brigitta M N Brinkman
Journal:  Clin Biochem       Date:  2004-07       Impact factor: 3.281

View more
  18 in total

Review 1.  Potential molecular targeting of splice variants for cancer treatment.

Authors:  Christopher A Blair; Xiaolin Zi
Journal:  Indian J Exp Biol       Date:  2011-11       Impact factor: 0.818

Review 2.  Hamartomatous polyposis syndromes.

Authors:  Daniel Calva; James R Howe
Journal:  Surg Clin North Am       Date:  2008-08       Impact factor: 2.741

3.  Exome sequencing implicates genetic disruption of prenatal neuro-gliogenesis in sporadic congenital hydrocephalus.

Authors:  Sheng Chih Jin; Weilai Dong; Adam J Kundishora; Shreyas Panchagnula; Andres Moreno-De-Luca; Charuta G Furey; August A Allocco; Rebecca L Walker; Carol Nelson-Williams; Hannah Smith; Ashley Dunbar; Sierra Conine; Qiongshi Lu; Xue Zeng; Michael C Sierant; James R Knight; William Sullivan; Phan Q Duy; Tyrone DeSpenza; Benjamin C Reeves; Jason K Karimy; Arnaud Marlier; Christopher Castaldi; Irina R Tikhonova; Boyang Li; Helena Perez Peña; James R Broach; Edith M Kabachelor; Peter Ssenyonga; Christine Hehnly; Li Ge; Boris Keren; Andrew T Timberlake; June Goto; Francesco T Mangano; James M Johnston; William E Butler; Benjamin C Warf; Edward R Smith; Steven J Schiff; David D Limbrick; Gregory Heuer; Eric M Jackson; Bermans J Iskandar; Shrikant Mane; Shozeb Haider; Bulent Guclu; Yasar Bayri; Yener Sahin; Charles C Duncan; Michael L J Apuzzo; Michael L DiLuna; Ellen J Hoffman; Nenad Sestan; Laura R Ment; Seth L Alper; Kaya Bilguvar; Daniel H Geschwind; Murat Günel; Richard P Lifton; Kristopher T Kahle
Journal:  Nat Med       Date:  2020-10-19       Impact factor: 53.440

Review 4.  Small bowel polyposis syndromes.

Authors:  Nadir Arber; Menachem Moshkowitz
Journal:  Curr Gastroenterol Rep       Date:  2011-10

5.  Hereditary hamartomatous polyposis syndromes: understanding the disease risks as children reach adulthood.

Authors:  Michael Manfredi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-03

Review 6.  PTEN hamartoma tumor syndromes.

Authors:  Gideon M Blumenthal; Phillip A Dennis
Journal:  Eur J Hum Genet       Date:  2008-09-10       Impact factor: 4.246

7.  Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome.

Authors:  Marcus G Pezzolesi; Petra Platzer; Kristin A Waite; Charis Eng
Journal:  Am J Hum Genet       Date:  2008-05       Impact factor: 11.025

Review 8.  Feedback regulation of RTK signaling in development.

Authors:  Cynthia L Neben; Megan Lo; Natalia Jura; Ophir D Klein
Journal:  Dev Biol       Date:  2017-10-26       Impact factor: 3.582

9.  Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers.

Authors:  K L Lachlan; A M Lucassen; D Bunyan; I K Temple
Journal:  J Med Genet       Date:  2007-05-25       Impact factor: 6.318

10.  Manipulating insulin signaling to enhance mosquito reproduction.

Authors:  Anam J Arik; Jason L Rasgon; Kendra M Quicke; Michael A Riehle
Journal:  BMC Physiol       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.